Table 1.
Baseline characteristics of 936 patients with stage II and III colorectal cancer
| Characteristic | Colon Cancer Patients (N=647) | Rectal Cancer Patients (N=289) | All patients (N=936) | Unadjusted HR for death | 95% CI |
|---|---|---|---|---|---|
| Age Group, years | |||||
| 65–74 | 276 (43%) | 153 (53%) | 429 (46%) | 1.00 | Reference |
| 75–84 | 287 (44%) | 112 (39%) | 399 (43%) | 1.56 | 1.27–1.91 |
| 85+ | 84 (13%) | 24 (8%) | 108 (11%) | 3.02 | 2.30–3.97 |
| Gender | |||||
| Female | 361 (56%) | 129 (45%) | 490 (52%) | 1.00 | Reference |
| Male | 286 (44%) | 160 (55%) | 446 (48%) | 1.19 | 0.99–1.43 |
| Race | |||||
| White | 488 (75%) | 257 (89%) | 745 (80%) | 1.00 | -- |
| Black | 159 (25%) | 32 (11%) | 191 (20%) | 1.23 | 0.99–1.54 |
| Comorbidity (ACE-27) | |||||
| None | 131 (20%) | 70 (24%) | 201 (21%) | 1.00 | Reference |
| Mild | 227 (35%) | 125 (43%) | 352 (38%) | 1.43 | 1.08–1.89 |
| Moderate | 193 (30%) | 68 (24%) | 261 (28%) | 2.13 | 1.60–2.82 |
| Severe | 96 (15%) | 26 (9%) | 122 (13%) | 2.48 | 1.78–3.44 |
| Treatment | |||||
| No chemotherapy | 426 (66%) | 153 (53%) | 579 (62%) | 1.00 | Reference |
| Chemotherapy | 221 (34%) | 136 (47%) | 357 (38%) | 0.89 | 0.73–1.07 |
| TNM Stage | |||||
| II | 373 (58%) | 128 (44%) | 501 (53%) | 1.00 | Reference |
| III | 274 (42%) | 161 (56%) | 435 (47%) | 1.66 | 1.38–2.00 |
Note: All the characteristics were significantly related to cancer site
HR: hazard ratio; CI: confidence intervals; ACE-27: Adult Comorbidity Evaluation-27